✦ LIBER ✦

Chemotherapy for ovarian cancer - trials, controversies and funding

✍ Scribed by Hawkins, RE

Book ID: 109838688
Publisher: Nature Publishing Group
Year: 1998
Tongue: English
Weight: 257 KB
Volume: 78
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.1998.698

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First-line chemotherapy for ovarian canc

First-line chemotherapy for ovarian cancer – the controversy continues

✍ Kaye, S B 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 42 KB

Intraperitoneal chemotherapy for ovarian

Intraperitoneal chemotherapy for ovarian cancer

✍ Gregory Friberg; Gini Fleming 📂 Article 📅 2003 🏛 Current Science Inc. 🌐 English ⚖ 295 KB

Chemotherapy for ovarian cancer: Current

Chemotherapy for ovarian cancer: Current concepts

✍ Vincent E. Herrin; J. Tate Thigpen 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB

Ovarian cancer is the most common gynecologic cancer and has the highest case-fatality rate of all gynecologic malignancies: over one-half of all women diagnosed with ovarian cancer die of their disease. Chemotherapy for epithelial ovarian carcinoma has evolved rapidly during the last 15 years. Demo

Consolidation/maintenance chemotherapy f

Consolidation/maintenance chemotherapy for ovarian cancer

✍ Maurie Markman 📂 Article 📅 2003 🏛 Current Science Inc. 🌐 English ⚖ 172 KB

Paclitaxel maintenance chemotherapy foll

Paclitaxel maintenance chemotherapy following intraperitoneal chemotherapy for ovarian cancer

✍ W.R. ROBINSON; N. DAVIS; A.S. ROGERS 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

Alternating multiagent chemotherapy for

Alternating multiagent chemotherapy for advanced ovarian cancer

✍ Enrique Hernandez; Neil B. Rosenshein; Jose Villar; Michael B. Dillon; David S. 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 344 KB

## Abstract A chemotherapy regimen consisting of hexamethylmelamine (H) 150 mg/ m^2^ orally days 1–14, cyclophosphamide (C) 500 mg/m^2^ IV day 1 of a 28‐day cycle with Adriamycin (A) 40 mg/m^2^ IV day 1 alternating with cisdiamminechloroplatinum (C‐P) 50 mg/m^2^ IV day 1 every other cycle was admin